Question: Where is the company that released Biricodar baseD?

full_context: Document 1: Codentify: Codentify is the name of a product serialization system developed and patented by Philip Morris International (PMI) for tobacco product authenticity verification and supply chain control. In the production process, each cigarette package is marked with a unique visible code (also called “Codentify”), that allows authenticating the code against a central server.
Document 2: Shire (pharmaceutical company): Shire Plc is a Jersey-registered, Irish-headquartered global specialty biopharmaceutical company. Originating in the United Kingdom with an operational base in the United States, its brands and products include Vyvanse, Lialda, and Adderall XR. Shire has its primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index. Shire has a secondary listing on NASDAQ.
Document 3: Mehmet Varol: Mehmet Varol was born in Ankara, Turkey, on June 6, 1986. He is a Turkish molecular biologist. He received his bachelor degree in 2010 from Department of Biology in Anadolu University, Turkey. He also received a second bachelor degree from Department of Business Administration in Anadolu University, Turkey. Between 2008-2009, he joined Socrates/Erasmus Exchange Program to go to Facoltá di Sc. MM.FF.NN. in Universitá Degli Studi Di Palermo, Italy, and he participated in Professor Maurizio Bruno's group to study about natural product isolation from plant materials. After graduating from Anadolu University, his career was continued by completing his master of science thesis entitled “Investigation of protective effect of lichen acids against ultraviolet rays”. He holds a PhD degree from Anadolu University, Turkey by the thesis entitled “Investigation of the angiogenesis-targeted treatment potentials of the small molecule structured natural compounds by epigenetic approach and molecular mechanisms on tumor development and invasion”. On the other hand, he studies to attain a second PhD from Department of Polymer Science and Technology, Faculty of Science, Eskisehir Osmangazi University, Turkey. His research interests include but not limited to controlled drug delivery systems, drug design and discovery, natural drug sources, photodynamic therapy and "in vitro" photo-biological experiments, conductive polymers and medical applications, reactive oxygen species and related cellular mechanisms. His current projects have been focused on metallophtalocyanines-mediated photodynamic therapy and related intracellular mechanisms of their action on adenocarcinoma and keratinocyte cell lines to detect their possible utilization on cancer and hypertrophic scarring diseases, and natural compounds to discover and develop their potentials as anti-angiogenic, anti-cancer, anti-oxidative drug ingredients. He currently works at the Department of Molecular Biology and Genetics, Faculty of Science, Mugla Sitki Kocman University, Turkey. He also contributes some academic journals as an editorial board member such as Biomedical Research, Journal of Applied Pharmacy etc.
Document 4: Vicki Sato: Vicki L. Sato is a professor of management practice at Harvard Business School and a professor of the practice in the department of molecular and cell biology at Harvard University. She earned her A.B. in Biology from Radcliffe College and her A.M. and Ph.D. in Biology from Harvard University focusing on the genetics of photosynthesis under the guidance of Paul Levine. She then did her postdoctoral work at University of California, Berkeley with Kenneth Sauer and Stanford Medical Center with Leonard Herzenberg where she shifted fields from biophysics into immunology. Initially, she returned to Harvard as a Professor in the Department of Cell and Developmental Biology. During that time, she co-taught immunology with Walter Gilbert who was beginning to found Biogen Inc. along with Phil Sharp, Charles Weissmann, and Kenneth Murray. During her sabbatical after eight years at Harvard, she became involved with a startup and eventually joined Biogen Inc. from 1984 to 1992 and left as the VP of Research and a member of the Scientific Board. She then joined Vertex Pharmaceuticals as the Chief Scientific Officer before becoming the Senior VP of Research and Development and ultimately serving as the President of Vertex Pharmaceuticals from 2000 to 2005. During her tenure, the drugs Avonex, Tysabri, and Telaprevir were developed.
Document 5: Massachusetts: Massachusetts ( or ), officially the Commonwealth of Massachusetts, is the most populous state in the New England region of the northeastern United States. It is bordered by the Atlantic Ocean to the east, the states of Connecticut and Rhode Island to the south, New Hampshire and Vermont to the north, and New York to the west. The state is named for the Massachusett tribe, which once inhabited the area. The capital of Massachusetts and the most populous city in New England is Boston. Over 80% of Massachusetts's population lives in the Greater Boston metropolitan area, a region influential upon American history, academia, and industry. Originally dependent on agriculture, fishing and trade, Massachusetts was transformed into a manufacturing center during the Industrial Revolution. During the 20th century, Massachusetts's economy shifted from manufacturing to services. Modern Massachusetts is a global leader in biotechnology, engineering, higher education, finance, and maritime trade.
Document 6: Biricodar: Biricodar (INN, codename VX-710, marketed as the dicitrate salt under the trade name Incel) is a pharmaceutical drug released by Vertex Pharmaceuticals in 1999 to help treat ovarian cancer patients.
Document 7: Osilodrostat: Osilodrostat (INN, USAN) (developmental code name LCI-699) is an orally active, non-steroidal corticosteroid biosynthesis inhibitor which is under development by Novartis for the treatment of Cushing's syndrome and pituitary hypersecretion (a specific subtype of Cushing's syndrome). It specifically acts as a potent and selective inhibitor of aldosterone synthase (CYP11B2) and at higher dosages of 11β-hydroxylase (CYP11B1). The drug was also under development for the treatment of heart failure, hypertension, and solid tumors, but development was discontinued for these indications. As of 2017, osilodrostat is in phase III and phase II clinical trials for treatment of pituitary ACTH hypersecretion and Cushing's syndrome, respectively.
Document 8: Victoria Hale: Victoria Hale founded the nonprofit pharmaceutical company The Institute for OneWorld Health in San Francisco, California in 2000 and was its chairman and CEO until 2008, when she became Chair Emeritus. She then went on to found Medicines360, a nonprofit pharmaceutical company dedicated to developing medicines for women and children, including pregnant women.
Document 9: Millennium Pharmaceuticals: Millennium Pharmaceuticals, Inc., The Takeda Oncology Company was a leading biopharmaceutical company based in Cambridge, Massachusetts. Millennium has gradually been absorbed by its parent Takeda and renamed Takeda Oncology. The Company marketed Velcade (bortezomib) for injection, a cancer product, and has a growing clinical development pipeline of product candidates. Millennium's research, development and commercialization activities focused in two therapeutic areas: oncology and inflammation. By applying its knowledge of the human genome, understanding of disease mechanisms and industrialized drug discovery platform, Millennium developed a line of new product candidates. It was one of the first companies to systematically search for genes linked to disease, but none of the drugs which it is marketing or has in clinical trial, with one partial exception, have been the results of that research. On May 14, 2008, Japanese company Takeda Pharmaceutical announced the completion of its acquisition of Millennium for US$25.00 per share in cash—a deal worth $8.8 billion. Takeda completed the acquisition through a tender offer and subsequent merger of a wholly owned subsidiary of Takeda into Millennium. Millennium is now a wholly owned subsidiary of Takeda.
Document 10: Vertex Pharmaceuticals: Vertex Pharmaceuticals is an American Pharmaceutical company based in Boston, Massachusetts.
Document 11: The Billion-Dollar Molecule: The Billion-Dollar Molecule is a book by journalist Barry Werth about the founding and early research efforts of the American biotechnology company Vertex Pharmaceuticals, which was founded in 1989 by Joshua Boger and was among the first biotechnology companies to adopt an explicit strategy of rational drug design as opposed to techniques based on combinatorial chemistry.
Document 12: Bose Corporation: Bose Corporation is an American privately held corporation, based in Framingham, Massachusetts, that designs, develops and sells audio equipment. Founded in 1964 by Amar Bose, the company sells its products throughout the world. Forbes estimates that in the 2015 financial year, Bose received revenue of US$3.5 billion and employed approximately 11,700 people.
Document 13: Rivaroxaban: Rivaroxaban, sold under the brand name Xarelto, among others, is an anticoagulant medication (blood thinner), which is taken by mouth. It is commonly used to prevent blood clots. It was initially developed by Bayer. In the United States, it is marketed by Janssen Pharmaceutica. It is the first available active direct factor Xa inhibitor which is taken by mouth. The maximum inhibition of factor Xa occurs four hours after a dose. The effects last approximately 8–12 hours, but factor Xa activity does not return to normal within 24 hours, so once-daily dosing is possible.
Document 14: Vital Pharmaceuticals: Vital Pharmaceuticals, Inc. (VPX Sports), which manufactures and distributes sports supplements under the brand name VPX, is a corporation located in United States, Florida founded in 1993 by Jack Owoc. Its market consists principally of fitness enthusiasts. The company produces sports nutrition supplements and performance beverages. Among VPX's better-known products are REDLINE Energy Drink, Power Rush and Bang.
Document 15: Simcere Pharmaceutical: Simcere Pharmaceutical Group or Simcere Pharmaceutical () is a manufacturer and supplier of branded generic pharmaceuticals in the Chinese market. Its focus is to introduce generic and pharmaceutical products for the treatment of diseases with high incidence and/or mortality rate. The Company has introduced a generic anti-stroke medication under the brand name, "Bicun", and an anti-cancer medication under the brand name, "Endu". Its products include antibiotics, anti-stroke medications, anti-inflammatory drugs, anti-cancer medications and other medicines. In addition, it has obtained approvals from the China State Food and Drug Administration (SFDA) to manufacture and sell over 210 other products.
ground_truth: Boston, Massachusetts